BioTelemetry Trumps Aevis' Takeover Bid For LifeWatch
Swiss firm LifeWatch has been offered a sweeter acquisition deal from BioTelemetry at a proposed CHF260m. The company was recently subject to a proposed takeover by investment firm Aevis Victoria SA.
You may also be interested in...
Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
M&A Analysis: April Showers Big Name Acquisitions
M&A deals rained down in April with the highest number of acquisitions of the year to date. The month saw 14 M&A deals, up by four from March's total, but still down from the 16 deals recorded in April 2016.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.